Boston Trust Walden Corp Raises Stock Holdings in Chemed Corporation (NYSE:CHE)

Boston Trust Walden Corp boosted its position in shares of Chemed Corporation (NYSE:CHE - Free Report) by 1.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 246,351 shares of the company's stock after buying an additional 4,179 shares during the period. Chemed accounts for approximately 1.1% of Boston Trust Walden Corp's portfolio, making the stock its 13th biggest holding. Boston Trust Walden Corp owned about 1.69% of Chemed worth $151,585,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Cushing Capital Partners LLC acquired a new position in shares of Chemed in the first quarter valued at approximately $237,000. Hanson & Doremus Investment Management increased its holdings in shares of Chemed by 14.3% in the first quarter. Hanson & Doremus Investment Management now owns 3,493 shares of the company's stock valued at $2,149,000 after purchasing an additional 437 shares during the period. Everpar Advisors LLC increased its holdings in shares of Chemed by 9.0% in the first quarter. Everpar Advisors LLC now owns 485 shares of the company's stock valued at $298,000 after purchasing an additional 40 shares during the period. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Chemed by 8.2% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 1,496 shares of the company's stock valued at $921,000 after purchasing an additional 114 shares during the period. Finally, Net Worth Advisory Group increased its holdings in shares of Chemed by 18.1% in the first quarter. Net Worth Advisory Group now owns 541 shares of the company's stock valued at $333,000 after purchasing an additional 83 shares during the period. Institutional investors and hedge funds own 95.85% of the company's stock.

Chemed Stock Up 0.2%

Shares of Chemed stock traded up $0.98 during trading on Friday, reaching $547.06. The company's stock had a trading volume of 245,728 shares, compared to its average volume of 105,026. Chemed Corporation has a 12-month low of $512.12 and a 12-month high of $623.61. The company has a market capitalization of $8.00 billion, a P/E ratio of 26.65, a price-to-earnings-growth ratio of 2.28 and a beta of 0.54. The business has a 50 day moving average price of $567.63 and a 200-day moving average price of $564.77.

Chemed (NYSE:CHE - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The company reported $5.63 earnings per share for the quarter, beating analysts' consensus estimates of $5.59 by $0.04. Chemed had a return on equity of 27.58% and a net margin of 12.40%. The firm had revenue of $646.94 million for the quarter, compared to the consensus estimate of $641.78 million. During the same period in the previous year, the business earned $5.20 earnings per share. The company's revenue for the quarter was up 9.8% compared to the same quarter last year. Research analysts predict that Chemed Corporation will post 21.43 EPS for the current fiscal year.

Chemed Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 17th. Shareholders of record on Thursday, May 29th were given a dividend of $0.50 per share. The ex-dividend date of this dividend was Thursday, May 29th. This represents a $2.00 dividend on an annualized basis and a yield of 0.37%. Chemed's payout ratio is 9.74%.

Analyst Ratings Changes

CHE has been the topic of a number of recent research reports. Royal Bank Of Canada boosted their target price on Chemed from $667.00 to $674.00 and gave the company an "outperform" rating in a report on Monday, April 28th. Wall Street Zen upgraded Chemed from a "hold" rating to a "buy" rating in a research note on Friday, March 7th.

Insiders Place Their Bets

In other Chemed news, CEO Kevin J. Mcnamara sold 1,000 shares of the business's stock in a transaction on Monday, March 31st. The stock was sold at an average price of $615.33, for a total transaction of $615,330.00. Following the sale, the chief executive officer now directly owns 101,679 shares in the company, valued at approximately $62,566,139.07. The trade was a 0.97% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Spencer S. Lee sold 1,500 shares of the business's stock in a transaction on Friday, May 16th. The stock was sold at an average price of $577.99, for a total value of $866,985.00. Following the sale, the executive vice president now owns 14,627 shares in the company, valued at approximately $8,454,259.73. The trade was a 9.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 5,500 shares of company stock worth $3,213,780. 3.29% of the stock is owned by corporate insiders.

Chemed Company Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.